Skip Nav Destination
Progress in Tumor Research
COX-2: A New Target for Cancer Prevention and TreatmentAvailable to Purchase
S.Karger AG
Volume
37
Status:
Available
ISBN electronic:
978-3-318-00940-8
ISBN print:
978-3-8055-7536-2
Discontinued Book Series:
Progress in Tumor Research
Publication date:
2003
Book Details
Numerous investigators have found increased levels of cyclooxygenase-2 (COX-2) in both pre-malignant and malignant tissues. Moreover, animals engineered to be COX-2 deficient or treated with a selective COX-2 inhibitor showed reduced tumor formation and growth. The present book reviews these findings suggesting that COX-2 is a valid molecular target for the prevention and treatment of cancer. The first chapters are devoted to the epidemiology of nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer, the pharmacology of COX-2 inhibitors and the regulation of COX-2 expression in human cancers. Besides, the book contains a series of chapters examining the link between COX-2 and cancer in specific organs (e.g. skin, breast, cervix, digestive tract, lung, etc.). Furthermore, several clinical trials assessing the potential of COX-2 inhibitors for preventing and treating cancer are described. The final chapter provides an up-to-date consideration of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. This state-of-the-art publication is recommended reading not only for medical and radiation oncologists, but also for pharmacologists, gastroenterologists and other subspecialists.
COX-2: A New Target for Cancer Prevention and Treatment
Edited by: A.J. Dannenberg, R.N. DuBois
https://doi.org/10.1159/isbn.978-3-318-00940-8
ISBN (print): 978-3-8055-7536-2
ISBN (electronic): 978-3-318-00940-8
Publisher: S.Karger AG
Published: 2003
Download citation file:
Digital Version
Pay-Per-View Access
$268.00
Print Version
COX-2
$268.00
Table of Contents
-
1 - 24: Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and CancerByJ.A. BaronJ.A. BaronDepartments of Medicine, and Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, N.H., USASearch for other works by this author on:
-
25 - 51: Pharmacology of COX-2 InhibitorsByP.C. IsaksonP.C. IsaksonPharmacia Research and Development, Peapack, N.J., USASearch for other works by this author on:
-
52 - 71: Regulation of COX-2 Expression in Human CancersByD.A. DixonD.A. DixonSurgical Oncology Research Laboratory, Departments of Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tenn., USASearch for other works by this author on:
-
72 - 89: Cyclooxygenase-2 and Skin CarcinogenesisByG. Fürstenberger;G. FürstenbergerDepartment of Eicosanoids and Epithelial Carcinogenesis, Deutsches Krebsforschungszentrum, Heidelberg, GermanySearch for other works by this author on:F. Marks;F. MarksDepartment of Eicosanoids and Epithelial Carcinogenesis, Deutsches Krebsforschungszentrum, Heidelberg, GermanySearch for other works by this author on:K. Müller-DeckerK. Müller-DeckerDepartment of Eicosanoids and Epithelial Carcinogenesis, Deutsches Krebsforschungszentrum, Heidelberg, GermanySearch for other works by this author on:
-
90 - 106: The Role of COX-2 in Breast and Cervical CancerByA.J. Dannenberg;A.J. DannenbergbMedicine, Weill Medical College of Cornell University, andcStrang Cancer Research Laboratory, New York, N.Y., USASearch for other works by this author on:L.R. HoweL.R. HoweaDepartments of Cell and Developmental Biology andcStrang Cancer Research Laboratory, New York, N.Y., USASearch for other works by this author on:
-
107 - 123: Cyclooxygenase-2: A Target for the Prevention and Treatment of Cancers of the Upper Digestive TractByN.K. Altorki;N.K. AltorkiaDepartments of Cardiothoracic Surgery andSearch for other works by this author on:K. Subbaramaiah;K. SubbaramaiahbMedicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, New York, N.Y., USASearch for other works by this author on:A.J. DannenbergA.J. DannenbergbMedicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, New York, N.Y., USASearch for other works by this author on:
-
124 - 137: Cyclooxygenase-2 and Colorectal CancerByR.N. DuBoisR.N. DuBoisDepartments of Medicine and Cell Biology, Vanderbilt University Medical Center and Department of Veterans Affairs Medical Center, Nashville, Tenn., USASearch for other works by this author on:
-
138 - 162: Cyclooxygenase-2 in Lung CancerByS.M. Dubinett;S.M. DubinettLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:S. Sharma;S. SharmaLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:M. Huang;M. HuangLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:M. Dohadwala;M. DohadwalaLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:M. Pold;M. PoldLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:J.T. MaoJ.T. MaoLung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif., USASearch for other works by this author on:
-
163 - 178: COX-2 Inhibitors and Other NSAIDs in Bladder and Prostate CancerByA.L. Sabichi;A.L. SabichiDepartment of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Tex., USASearch for other works by this author on:S.M. LippmanS.M. LippmanDepartment of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Tex., USASearch for other works by this author on:
-
179 - 192: Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor AngiogenesisByS. Gately;S. GatelyaNeoPharm Inc., Department of Translational Medicine, Lake Forest, Ill., USA andSearch for other works by this author on:R. KerbelR. KerbelbSunnybrook and Women’s College Health Sciences Center, Molecular and Cellular Biology Research and Department of Medical Biophysics, University of Toronto, Toronto, CanadaSearch for other works by this author on:
-
193 - 209: Potential for Combined Modality Therapy of Cyclooxygenase Inhibitors and RadiationByD. Saha;D. SahaDepartment of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tenn., USASearch for other works by this author on:H. ChoyH. ChoyDepartment of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tenn., USASearch for other works by this author on:
-
210 - 242: Non-Steroidal Anti-Inflammatory and Cyclooxygenase-2-Selective Inhibitors in Clinical Cancer Prevention TrialsByE.T. Hawk;E.T. HawkGastrointestinal & Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Md., USASearch for other works by this author on:J.L. Viner;J.L. VinerGastrointestinal & Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Md., USASearch for other works by this author on:A. UmarA. UmarGastrointestinal & Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Md., USASearch for other works by this author on:
-
243 - 260: Chemotherapy with Cyclooxygenase-2 Inhibitors in the Treatment of Malignant Disease: Pre-Clinical Rationale and Preliminary Results of Clinical TrialsByC.D. Blanke;C.D. BlankeaOregon Health & Science University, Portland, Oreg. andSearch for other works by this author on:J.L. MasferrerJ.L. MasferrerbPharmacia Corporation, Chesterfield, Mo., USASearch for other works by this author on:
-
261 - 283: Role of COX-Independent Targets of NSAIDs and Related Compounds in Cancer Prevention and TreatmentByJ.-W. Soh;J.-W. SohDepartment of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians & Surgeons, Columbia University, New York, N.Y., USASearch for other works by this author on:B. WeinsteinB. WeinsteinDepartment of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians & Surgeons, Columbia University, New York, N.Y., USASearch for other works by this author on:
